`Cloutier et al.
`
`(10) Patent N0.:
`(45) Date of Patent:
`
`US 6,756,033 B2
`*Jun. 29, 2004
`
`US006756033B2
`
`(54) METHOD FOR DELIVERING BENZINDENE
`PROSTAGLANDINS BY INHALATION
`
`(75) Inventors: Gilles Cloutier, Chapel Hill, NC (US);
`James Crow, Chapel Hill, NC (US);
`Michael Wade, Chapel Hill, NC (US);
`Richard E. Parker, Spring Hill, TN
`(US); James E. Loyd, Nashville, TN
`(Us)
`(73) Assignee: United Therapeutics Corporation,
`Washington, DC (US)
`
`( * ) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`USC 154(b) by 0 days.
`
`This patent is subject to a terminal dis
`clairner.
`
`(21) Appl. No.: 10/212,149
`(22) Filed:
`Aug. 6, 2002
`(65)
`Prior Publication Data
`
`US 2003/0053958 A1 Mar. 20, 2003
`
`Related US. Application Data
`
`(63) Continuation of application No. 09/525,471, ?led on Mar.
`15, 2000, now Pat. NO. 6,521,212.
`(60) Provisional application No. 60/124,999, ?led on Mar. 18,
`1999.
`
`(51) Int. Cl? .......................... .. A61K 9/12; A61K 9/14;
`A61K 31/19
`
`(52) US. Cl. ......................... .. 424/45; 424/46; 424/489;
`514/571; 514/573; 560/56
`(58) Field of Search .......................... .. 424/45, 46, 489,
`424/305; 514/454, 569, 573, 571
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,306,075 A 12/1981 Aristoff
`4,895,719 A * 1/1990 Radhakrishnan et al.
`5,153,222 A 10/1992 Tadepalli et al.
`514/454
`5,190,972 A * 3/1993 Dumble .......... ..
`6,521,212 B1 * 2/2003 Cloutier et al. ............. .. 424/45
`
`424/45
`
`FOREIGN PATENT DOCUMENTS
`
`EP
`EP
`W0
`
`0 159 784 A1 10/1985
`1 161 234 B1
`12/2001
`WO 99/25357 A1
`5/1999
`
`* cited by examiner
`
`Primary Examiner—Michael G. Hartley
`Assistant Examiner—Mina Haghighatian
`(74) Attorney, Agent, or Firm—Foley & Lardner LLP
`(57)
`ABSTRACT
`
`A method of delivering benZindene prostaglandins to a
`patient by inhalation is discussed. AbenZindene prostaglan
`din known as UT-15 has unexpectedly superior results When
`administered by inhalation compared to parenterally admin
`istered UT-15 in sheep With induced pulmonary hyperten
`s1on.
`
`10 Claims, 18 Drawing Sheets
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 1 of 27
`
`
`
`U.S. Patent
`
`Jun. 29,2004
`
`Sheet 1 0f 18
`
`US 6,756,033 B2
`
`F .UE
`
`low
`
`I or
`
`.. mr
`
`iggsbmIeov
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 2 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 2 0f 18
`
`US 6,756,033 B2
`
`6
`
`4
`
`2
`
`O
`
`FIG. 2 BASELINE // UT15
`
`24-1
`
`125—
`
`PPA (cmHzO)
`
`20
`
`I
`(D
`1-
`
`N
`1
`
`»\\\\\\\\\\\\\\\\\\\\\§ PSA (mmHg)
`
`100
`
`l
`Lo
`N
`
`0
`no
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 3 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 3 0f 18
`
`US 6,756,033 B2
`
`
`
`
`
`E2955 E5205 @5255
`
`82 O3 O3
`2 5 E S m: S wzzmmé
`
`m’
`
`W 25 802M252 0 18m
`
`
`
`m .u_.._ [Os
`
`£5 68%: o
`
`0 108 #5:
`2, EE
`
`18
`
`109
`
`5%:
`
`_ _ _ _ o
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 4 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 4 0f 18
`
`US 6,756,033 B2
`
`89 O8
`25 2 S
`
`
`
`E535 @525
`
`@5955
`
`SN
`2 5 mzzwmé
`
`cm
`
`
`
`5H3 m30zm><mPz_ O
`
`
`
`mzb ._OmOmm< 0
`
`I o:
`
`I 2.:
`
`wmammmml
`
`aIEé
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 5 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 5 0f 18
`
`US 6,756,033 B2
`
`
`
`
`
`E52? E523 2533
`
`89 08 0mm
`25 E 5 2 5 M2595
`
`F _ _ _
`
`m .UE
`
`
`
`5H3 m30zm><mPZ O
`
`
`
`5.5 ._OwOmm< O
`
`mmpmwmg
`
`wgozms
`
`$528
`
`SNIEQV
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 6 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 6 6f 18
`
`US 6,756,033 B2
`
`£5
`89
`
`25
`
`253mg
`25??
`2.535
`
`3“
`m: 5 M2595
`
`
`
`3.5 m30zm><mFz_ 0
`
`
`
`$15 ._OmOEm< O
`
`low
`
`12,
`
`25:5
`
`mmDmmmml
`
`695
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 7 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 7 0f 18
`
`US 6,756,033 B2
`
`89 o8 o8 , m E: 2 5 Q 5
`
`@523 E52? 2525
`
`
`
`
`
`wzzwwé
`
`5. P3 w30zm><mPz_ O
`2L3 ._OmOmw< O
`
`
`
`F5
`
`[or
`
`mwsmwwma
`252
`E5
`
`695
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 8 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 8 0f 18
`
`US 6,756,033 B2
`
`m? 5
`
`8 5
`
`2 S
`
`2555
`E5955
`E5335
`
`w .UE
`
`2. .5 ._OmOmm<
`
`m? .5 mDOZm><E.Z_ O
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 9 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 9 0f 18
`
`US 6,756,033 B2
`
`E555
`5893
`@535
`
`m? .5
`
`a 5
`
`21.5
`
`m .2"
`
`m? 5 ._OmOmm< O
`
`l or
`
`| w
`
`I q :MEEEQNIEQV
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 10 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 10 0f 18
`
`US 6,756,033 B2
`
`82
`m? .5
`
`com
`2. .5
`
`EEEBE
`2522
`2525
`
`0mm
`
`o_. .UE
`
`P
`
`1 O8
`
`I O2
`
`I 02 BE
`£52
`
`#5:
`
`| om
`
`O
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 11 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 11 0f 18
`
`US 6,756,033 B2
`
`
`
`
`
`2533 E52? E52?
`
`89 0% E
`
`g 5 2 5 2 5 @833 wzzmmé
`
`I .UE
`
`m: 5 $052526
`2 5 Jowommz o
`
`_ _ _ _
`
`i, wmjwwmml
`mag/m;
`
`$550
`
`6% as
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 12 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 12 0f 18
`
`US 6,756,033 B2
`
`
`
`
`
`E555 E255 Eggs
`
`89 8,“, 0mm
`
`
`
`5 5 £5 E 5 $035 mzzwwé
`
`_ _ _ _ _
`
`2. H3 w30zm><m._.z_ 0
`mp .5 JOmOmmE O
`
`l 03
`
`l ow?
`
`l o?
`
`@125
`
`- wmzwmwmm
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 13 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 13 0f 18
`
`US 6,756,033 B2
`
`82 8 S
`
`2535
`2555
`E535
`
`0% 2 5 _
`
`8m 2 5 _
`
`@835
`
`_ _
`
`2 .0E
`
`2. .5 40wOmm< O
`
`low
`
`mmjwwmml
`
`J2EE
`
`E2053
`
`@152
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 14 of 27
`
`
`
`US. Patent
`
`Jun. 29, 2004
`
`Sheet 14 0f 18
`
`US 6,756,033 B2
`
`3.UE
`
`mrF:ark:mwha
`
`
`
`EEEBEEEBxBSEEBVES
`oooficom0mm
`
`8035
`
`mz_._mm<m 9H3m302m><mpz_0EH:
`
`ww
`
`06¢t¢t
`
`JOmOmm/x0
`
`m_
`
`OF
`
`no
`
`..mmmammmma
`
`AONIEOV
`
`AmmJ
`
`3m:
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 15 of 27
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 15 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 15 0f 18
`
`US 6,756,033 B2
`
`_
`
`3.5
`
`o m P
`_ mm
`
`.5 $033
`
`2 .0E
`
`m? .5 ._OwOmm_< O
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 16 of 27
`
`
`
`US. Patent
`
`Jun. 29, 2004
`
`Sheet 16 0f 18
`
`US 6,756,033 B2
`
`
`
`EEEBEEEEVECVEEBxBe
`
`
`009com0mm
`
`
` 2..5mr._.Dm_..5$0vamzjmm<m m_.,5wDOZm><E.z_OmP.5Aomomm<O
`
`2d:
`
`mm
`
`om
`
`_.
`
`m>m<ZO§Sa
`
`mfizom<>
`
`mozibfimm
`
`S:Lgrgebmxee
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 17 of 27
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 17 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 17 0f 18
`
`US 6,756,033 B2
`
`E522 E555 5533
`
`89 08 SN
`2 S 8 5 2 S wzzmmé
`
`
`
`
`
`_ _ _ _
`
`t .0;
`
`3 H3 m:Ozm_><m.rz_ 0
`mg: ._OwOmm< I
`
`
`
`[mm
`
`low
`
`a 9
`
`AONIEOV
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 18 of 27
`
`
`
`U.S. Patent
`
`Jun. 29, 2004
`
`Sheet 18 0f 18
`
`US 6,756,033 B2
`
`coo? com
`
`
`
`
`
`EEBVEE E5355 EEMWMBE
`
`
`
`
`
`m? ._.D m? ._.D m_. .PD 9535 wzjmw<m
`
`_ w m _ _
`
`2 .wt
`
`m? .5 w30zw><mPz_ O
`m? .5 ._OmOmm< O
`
`[ow
`
`[om
`
`low
`
`low
`
`l9.
`
`low
`Sail
`6%5
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 19 of 27
`
`
`
`US 6,756,033 B2
`
`1
`METHOD FOR DELIVERING BENZINDENE
`PROSTAGLANDINS BY INHALATION
`
`CROSS-REFERENCE TO RELATED PATENT
`APPLICATIONS
`This application is a continuation of US. application Ser.
`No. 09/525,471, ?led on Mar. 15, 2000, now US. Pat. No.
`6,521,212 Which claims priority to provisional U.S. Appli
`cation Serial No. 60/124,999, ?led Mar. 18, 1999.
`BACKGROUND OF THE INVENTION
`BenZindene prostaglandins are noW knoWn to be useful to
`treat a variety of conditions. US. Pat. No. 5,153,222
`describes the use of a preferred class of benZindene pros
`taglandins in the treatment of pulmonary hypertension,
`including both primary and secondary pulmonary hyperten
`sion. In particular, this patent discusses the use of the
`compound compound 9-deoxy-2‘,9-alpha-methano-3-oxa-4,
`5,6-trinor-3,7-(1‘,3‘-interphenylene)-13,14-dihydro
`prostaglandin F1 (also knoWn as UT-15).
`HoWever, this patent does not speci?cally suggest the
`administration of such benZindene prostaglandins by inha
`lation or the surprising bene?ts that result from their deliv
`ery by inhalation.
`US. Pat. No. 4,306,075 describes a large group of car
`bacyclin analogs, including benZindene prostaglandins,
`Which produce various pharmacological responses, such as
`inhibition of platelet aggregation, reduction of gastric
`secretion, and bronchodilation. It is indicated that the com
`pounds have useful application as anti-thrombotic agents,
`anti-hypertension agents, anti-ulcer agents, and anti-asthma
`agents. The patent does mention administration by inhala
`tion. The patent speci?cally discloses the compound UT-15
`in Example 33. HoWever, this patent provides only limited
`biological data relating to the use of such compounds. At
`column 59, example 31, the patent discloses a compound
`that is structurally similar to that of example 33 (UT-15), but
`it is not the same compound. Example 31 discloses (column
`59, lines 41—45) that “[t]he compounds [sic] 9-deoxy-2‘,9ot
`methano-3-oxa-4,5,6-trinor-3,7-(1‘,3‘-interphenylene)
`PGFl, methyl ester, given to a rat orally at a dose of 1 mg/kg
`loWered blood pressure 44 mmHg. After 52 min the blood
`pressure Was still loWer 14 mm.”
`All blood is driven through the lungs via the pulmonary
`circulation in order, among other things, to replenish the
`oxygen Which it dispenses in its passage around the rest of
`the body via the systemic circulation. The How through both
`circulations is in normal circumstances equal, but the resis
`tance offered to it in the pulmonary circulation is generally
`much less than that of the systemic circulation. When the
`resistance to pulmonary blood ?oW increases, the pressure in
`the circulation is greater for any particular ?oW. This is
`referred to as pulmonary hypertension. Generally, pulmo
`nary hypertension is de?ned through observations of pres
`sures above the normal range pertaining in the majority of
`people residing at the same altitude and engaged in similar
`activities.
`Most often pulmonary hypertension is a manifestation of
`an obvious or explicable increase in resistance, such as
`obstruction to blood ?oW by pulmonary emboli, malfunction
`of the heart’s valves or muscle in handling blood after its
`passage through the lungs, diminution in pulmonary vessel
`caliber as a re?ex response to hypoventilation and loW
`oxygenation, or a mismatch of vascular capacity and essen
`tial blood ?oW, such as shunting of blood in congenital
`abnormalities or surgical removal of lung tissue. Such
`pulmonary hypertension is referred to as secondary hyper
`tension.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`55
`
`60
`
`65
`
`2
`There remain some cases of pulmonary hypertension
`Where the cause of the increased resistance is as yet inex
`plicable. They are described as primary pulmonary hyper
`tension (PPH) and are diagnosed by and after exclusion of
`the causes of secondary pulmonary hypertension. Despite
`the possibility of a varied etiology, cases of primary pulmo
`nary hypertension tend to comprise a recogniZable entity.
`Approximately 65% are female and young adults are most
`commonly af?icted, though it has occurred in children and
`patients over 50. Life expectancy from the time of diagnosis
`is short, about 3 to 5 years, though occasional reports of
`spontaneous remission and longer survival are to be
`expected given the nature of the diagnostic process.
`Generally, hoWever, progress is inexorable via syncope and
`right heart failure and death is quite often sudden.
`Pulmonary hypertension refers to a condition associated
`With an elevation of pulmonary arterial pressure (PAP) over
`normal levels. In humans, a typical mean PAP is approxi
`mately 12—15 mm Hg. Pulmonary hypertension, on the other
`hand, is sometimes marked by PAP increases by at least 5 to
`10 mm Hg over normal levels. PAP readings as high as 50
`to 100 mm Hg over normal levels have been reported. When
`the PAP markedly increases, plasma can escape from the
`capillaries into the lung interstitium and alveoli. Fluid
`buildup in the lung (pulmonary edema) can result, With an
`associated decrease in lung function that can in some cases
`be fatal.
`Pulmonary hypertension may either be acute or chronic.
`Acute pulmonary hypertension is often a potentially revers
`ible phenomenon generally attributable to constriction of the
`smooth muscle of the pulmonary blood vessels, Which may
`be triggered by such conditions as hypoxia (as in high
`altitude sickness), acidosis, in?ammation, or pulmonary
`embolism. Chronic pulmonary hypertension is characteriZed
`by major structural changes in the pulmonary vasculature,
`Which result in a decreased cross-sectional area of the
`pulmonary blood vessels. This may be caused by, for
`example, chronic hypoxia, thromboembolism, or unknoWn
`causes (idiopathic or primary pulmonary hypertension).
`Pulmonary hypertension has been implicated in several
`life-threatening clinical conditions, such as adult respiratory
`distress syndrome (“ARDS”) and persistent pulmonary
`hypertension of the neWborn (“PPHN”). Zapol et al., Acute
`Respiratory Failure, p. 241—273, Marcel Dekker, NeW York
`(1985); Peckham, J. Ped. 9311005 (1978). PPHN, a disorder
`that primarily affects full-term infants, is characteriZed by
`elevated pulmonary vascular resistance, pulmonary arterial
`hypertension, and right-to-left shunting of blood through the
`patent ductus arteriosus and foramen ovale of the neWborn’s
`heart. Mortality rates range from 12—50%. Fox, Pediatrics
`59:205 (1977); DWoretZ, Pediatrics 84:1 (1989). Pulmonary
`hypertension may also result in a potentially fatal heart
`condition knoWn as “cor pulmonale”, or pulmonary heart
`disease. Fishman, “Pulmonary Diseases and Disorders” 2”d
`Ed., McGraW-Hill, NY. (1988).
`The treatment of pulmonary hypertension by the
`parenteral administration of certain prostaglandin
`endoperoxides, such as prostacyclin (also knoWn as ?olan),
`is also knoWn and is the subject of US. Pat. No. 4,883,812.
`Prostacyclin has been administered by inhalation and is used
`to treat pulmonary hypertension by inhalation.
`Anesthesiology, vol. 82, no. 6, pp. 1315—1317.
`
`SUMMARY OF THE INVENTION
`
`This invention relates to the administration of a therapeu
`tically effective amount of a benZindene prostaglandin to a
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 20 of 27
`
`
`
`US 6,756,033 B2
`
`3
`mammal in need thereof by inhalation. More particularly,
`the invention relates to a method of treating pulmonary
`hypertension by administering an effective amount of a
`benzindene prostaglandin to a mammal in need thereof by
`inhalation.
`
`Inhalation of benzindene prostaglandins provides uneX-
`pectedly superior results compared to parenteral adminis-
`tration of benzindene prostaglandins.
`BRIEF DESCRIPTION OF THE DRAWINGS
`
`FIG. 1 is a graph of pulmonary vascular resistance
`(cmHzO*min/liter) intravenously induced by U44069 over
`time (min).
`FIG. 2 describes the effects of a high dose of UT15, given
`as an aerosol, on the hemodynamic variables of the sheep.
`Specifically, FIG. 2 depicts the effects of the aerosolized
`UT15 administered to the sheep intravenously induced with
`U44069 on systemic arterial pressure(PSA or PSYS); on
`pulmonary arterial pressure (PPA); and pulmonary vascular
`resistance (PVR), respectively.
`FIG. 3 is the dose-response effect of intravenously infused
`LT15 and aerosolized UT15 on the heart rate during base-
`line conditions.
`
`FIG. 4 is the dose-response effect of intravenously infused
`LT15 and aerosolized UT15 on the systemic arterial pres-
`sure during baseline conditions.
`FIG. 5 is the dose-response effect of intravenously infused
`LT15 and aerosolized UT15 on the central venous pressure
`during baseline conditions.
`FIG. 6 is the dose-response effect of intravenously infused
`LT15 and aerosolized UT15 on the pulmonary arterial
`pressure during baseline conditions.
`FIG. 7 is the dose-response effect of intravenously infused
`LT15 and aerosolized UT15 on the left atrial pressure
`during baseline conditions.
`FIG. 8 is the dose-response effect of intravenously infused
`LT15 and aerosolized UT15 on cardiac output during base-
`line conditions.
`
`
`
`FIG. 9 is the dose-response effect of intravenously infused
`LT15 and aerosolized UT15 on pulmonary vascular resis-
`tance during baseline conditions.
`FIG. 10 is the dose-response effect on the heart rate of
`intravenously infused UT15 and aerosolized UT15 during
`intravenously infused U44069.
`FIG. 11 is the dose-response effect of intravenously
`infused and aerosolized UT15 on central venous pressure
`during intravenously infused U44069.
`FIG. 12 is the dose-response effect of intravenously
`infused and aerosolized UT15 on systemic arterial pressure
`during intravenously infused U44069.
`FIG. 13 is the dose-response effect of intravenously
`infused and aerosolized UT15 on pulmonary arterial pres-
`sure during intravenously infused U44069.
`FIG. 14 is the dose-response effect of intravenously
`infused and aerosolized UT15 on left atrial pressure during
`intravenously infused U44069.
`FIG. 15 is the dose-response effect of intravenously
`infused and aerosolized UT15 on cardiac output during
`intravenously infused U44069.
`FIG. 16 is the dose-response effect of intravenously
`infused and aerosolized UT15 on pulmonary vascular resis-
`tance during intravenously infused U44069.
`FIG. 17 is the dose-response effect of intravenously
`infused and aerosolized UT15 on pulmonary vascular driv-
`ing pressure (PPA minus PLA) during baseline conditions.
`
`4
`FIG. 18 is the dose-response effect of intravenously
`infused and aerosolized UT15 on pulmonary vascular driv-
`ing pressure (PPA-PLA) during intravenously infused
`U44069.
`
`DETAILED DESCRIPTION OF THE
`INVENTION
`
`a :a
`Unless otherwise specified, all references to a
`mean at least one.
`
`or “an”
`
`One embodiment of the present invention is a method of
`delivering a benzindene prostaglandin or a pharmaceutically
`acceptable salt or ester thereof to a mammal in need thereof
`by inhalation.
`Apreferred group of benzindene prostaglandins for deliv-
`ery by inhalation according to the present invention is as
`follows:
`
`HOZC
`
`X/
`\(CH2)o
`
`(1)
`
` A
`on”...E
`
`s‘t
`O
`
`H
`
`wherein a is an integer of from 1 to 3; X and Y, which may
`be the same or different, are selected from —O— and
`—CH2—; R is —(CH2)5—R1 wherein R1 is hydrogen or
`methyl, or R is cyclohexyl, or R is —CH(CH3)CH2C CCH3;
`and the dotted line represents an optional double bond; or a
`physiologically acceptable salt or acid derivative thereof.
`The most preferred benzindene prostaglandin is UT—15,
`which is 9-deoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,
`7-(1',3'-interphenylene)-13,14-dihydro-prostaglandin F1.
`“Inhalation” delivery in the context of this invention
`refers to the delivery of the active ingredient or combination
`of active ingredients through a respiratory passage, wherein
`the mammal in need of the active ingredient(s) inhales the
`active ingredient(s) through the mammal’s airways, such as
`the nose or mouth.
`
`Active ingredients, which are aerosolized, atomized, and/
`or nebulized for delivery by inhalation according to the
`present invention include liquid formulations comprising a
`benzindene prostaglandin, such as UT—15, alone or in com-
`bination with other active ingredients described below.
`UT—15 may be used as a free acid or in the form of a
`pharmaceutically acceptable salt or ester or other acid
`derivative. In addition, sustained release formulations com-
`prising UT—15 may be used, including PEGylated forms
`and/or protein-conjugated forms of UT—15.
`The term “acid derivative” is used herein to describe C,
`alkyl esters and amides,
`including amides wherein the
`nitrogen is optionally substituted by one or two C1_4 alkyl
`groups.
`
`The invention also includes bioprecursors or “pro-drugs”
`of UT—15, that is, compounds which are converted in vivo to
`UT—15 or its pharmaceutically active derivatives thereof.
`Further aspects of the present invention are concerned
`with the use of UT—15, or a pharmaceutically acceptable salt
`or acid derivative thereof, in the manufacture of a medica-
`ment for the treatment of peripheral vascular disease
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 21 of 27
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 21 of 27
`
`
`
`US 6,756,033 B2
`
`5
`invention extends to non-physiologically
`The present
`acceptable salts of UT—15 which may be used in the prepa-
`ration of the pharmacologically active compounds of the
`invention. The physiologically acceptable salts of UT—15
`include salts derived from bases.
`Base salts include ammonium salts, alkali metal salts such
`as those of sodium and potassium, alkaline earth metal salts
`such as those of calcium and magnesium, salts with organic
`bases such as dicyclohexylamine and N-methyl-D-
`glucamine, and salts with amino acids such as arginine and
`lysine.
`Quaternary ammonium salts can be formed, for example,
`by reaction with lower alkyl halides, such as methyl, ethyl,
`propyl, and butyl chlorides, bromides, and iodides, with
`dialkyl sulphates, with long chain halides, such as decyl,
`lauryl, myristyl, and stearyl chlorides, bromides, and
`iodides, and with aralkyl halides, such as benzyl and phen-
`ethyl bromides.
`Optionally, one or more pharmaceutically acceptable car-
`riers or excipients may be included in the formulation to be
`aerosolized, atomized, or nebulized according to the inven-
`tion.
`
`Apreferred solution for administration by inhalation with
`a nebulizer includes a sterile solution of UT—15 comprising
`UT—15, sodium citrate, citric acid, sodium hydroxide,
`sodium chloride, and meta-cresol. Amore preferred solution
`is prepared by mixing 0.125 grams UT—15, 1.25 grams
`hydrous sodium citrate, 0.125 grams of anhydrous citric
`acid, 0.05 grams of sodium hydroxide, and approximately
`250 ml of water for injection.
`Preferably, a nebulizer, inhaler, atomizer or aerosolizer is
`used which forms droplets from a solution or liquid con-
`taining the active ingredient(s). The droplets are preferably
`less than 10 micrometers in diameter. One preferred nebu-
`lizer is the AM-601 MEDICATOR AEROSOL DELIVERY
`
`SYSTEMTM (a nebulizer manufactured by Healthline Medi-
`cal in Baldwin Park, Calif.).
`Alternatively, solid formulations, usually in the form of a
`powder, may be inhaled in accordance with the present
`invention. In such case, the particles are preferably less than
`10 micrometers in diameter, and more preferably, less than
`5 micrometers in diameter.
`
`This invention further relates to delivering a benzindene
`prostaglandin and/or its salts pr esters by inhalation for
`applications where inhalation delivery is appropriate for the
`treatment of that particular condition. Benzindene
`prostaglandins, including UT—15 and its salts or esters, have
`been shown to be useful for multiple applications. For
`example, UT—15 has been shown to exhibit a potent anti-
`aggregatory action on blood platelets, and therefore has a
`particular utility in mammals as an anti-thrombotic agent.
`Further known uses of UT-15 include treatments of pheriph-
`eral vascular disease (covered in co-pending application Ser.
`No. 09/190,450, now US. Pat. No. 6,054,486, the entire
`contents of which are incorporated by reference herein). In
`the case of treating peripheral vascular disease by inhalation
`of a benzindene prostaglandin of the present invention, the
`dosage for inhalation, taking into account that some of the
`active ingredient is breathed out and not taken into the
`bloodstream, should be sufficient to deliver an amount that
`is equivalent to a daily infusion dose in the range of 25 pg
`to 250 mg; typically from 0.5 Mg to 2.5 mg, preferably from
`7 Mg to 285 pg, per day per kilogram bodyweight. For
`example, an intravenous dose in the range 0.5 pg to 1.5 mg
`per kilogram bodyweight per day may conveniently be
`administered as an infusion of from 0.5 ng to 1.0 pg per
`kilogram bodyweight per minute. A preferred dosage is 10
`ng/kg/min.
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`65
`
`6
`Benzindene prostaglandins, including UT—15 and its salts
`or esters, may also be administered according to the present
`invention by inhalation to reduce and control excessive
`gastric secretion, thereby reducing or avoiding gastrointes-
`tinal ulcer formation, and accelerating the healing of ulcers
`and lesions already present in the gastrointestinal tract. In
`addition, benzindene prostaglandins may also be adminis-
`tered according to the present invention by inhalation to treat
`congestive heart failure,
`to reduce inflammation and/or
`pulmonary hypertension associated with lung transplants.
`Benzindene prostaglandins, including UT—15 and its salts
`or esters, further exhibit vasodilatory action on blood vessels
`and therefore have a particular utility as anti-hypertensives
`for
`the treatment of high blood pressure in mammals,
`including man. Use as an anti-hypertensive (or hypotensive
`agent) may be accomplished by administering a pharmaceu-
`tical composition containing a benzindene prostaglandin,
`including UT-15.
`including UT—15, may be
`Benzindene prostaglandins,
`used according to the present invention by inhalation to treat
`any condition where it is desired to reduce blood pressure,
`inhibit platelet aggregation, to reduce the adhesive character
`of platelets, and/or to treat or prevent
`the formation of
`thrombi in mammals, including man. For example, they may
`be used in the treatment and prevention of myocardial
`infarcts and in the treatment of peripheral vascular disease,
`to treat and prevent post-operative thrombosis, to promote
`patency of vascular grafts following surgery, and to treat
`complications of arteriosclerosis and conditions such as
`atherosclerosis, blood clotting defects due to lipemia, and
`other clinical conditions in which the underlying etiology is
`associated with lipid imbalance or hyperlipidemia.
`Moreover, benzindene prostaglandins, including UT—15 and
`its salts or esters, have a further utility in the promotion of
`wound healing in mammals, including man.
`Benzindene prostaglandins, including UT—15 and its salts
`or esters, may also be used as additives to blood, blood
`products, blood substitutes, and other fluids, which are used
`in artificial extra-corporeal circulation and perfusion of
`isolated body portions, e.g.,
`limbs and organs, whether
`attached to the original body, detached and being preserved
`or prepared for transplant, or attached to a new body. During
`these circulations and perfusions, aggregated platelets tend
`to block the blood vessels and portions of the circulation
`apparatus. This blocking is avoided by the presence of
`UT—15. For this purpose, UT-15 or its salts or esters may be
`introduced by inhalation until
`it reaches a level
`in the
`circulating blood, the blood of the donor animal, or the blood
`of the perfused body portion, or to two or all of those
`equivalent to a steady state dose of 0.001 micrograms to 10
`micrograms, per liter of circulating fluid. Another embodi-
`ment is to use UT—15 in laboratory animals, e.g., cats, dogs,
`rabbits, monkeys and rats, for these purposes in order to
`develop new methods and techniques for organ and limb
`transplants.
`In accordance with the present invention, a benzindene
`prostaglandin is delivered by inhalation to a patient in need
`thereof in a “therapeutically effective amount”. A “thera-
`peutically effective amount” refers to that amount that has
`therapeutic effects on the condition intended to be treated or
`prevented. For example, an “antihypertensive effective
`amount” refers to that amount in which the effects from
`
`pulmonary hypertension, and particularly, pulmonary arte-
`rial pressure (PAP), are reduced towards a normal level
`relative to hypertensive levels, or maintained at normal
`levels. The precise amount that is considered effective for a
`particular therapeutic purpose will, of course, depend upon
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 22 of 27
`
`WATSON LABORATORIES, INC. , IPR2017-01621, Ex. 1057, p. 22 of 27
`
`
`
`US 6,756,033 B2
`
`7
`the specific circumstances of the patient being treated and
`the magnitude of effect desired by the patient’s doctor.
`Titration to effect may be used to determine proper dosage.
`Such formulations, both for veterinary and for human
`medical use, of the present invention comprise the active
`ingredient, a benzindene prostaglandin or salt or ester
`thereof,
`together with one or more pharmacologically
`acceptable carriers therefor and optionally other therapeutic
`ingredients. The carrier(s) must be “acceptable” in the sense
`of being compatible with the other ingredients of the for-
`mulation and not deleterious to the recipient thereof.
`Furthermore, the formulations may conveniently be pre-
`sented in unit dosage form and may be prepared by any of
`the methods well known in the art of pharmacy. All methods
`include the step of bringing into association the active
`ingredient with the carrier which constitutes one or more
`pharmacologically acceptable accessory ingredients.
`The invention further relates to a method of treating
`pulmonary hypertension by inhalation of a benzindene pros-
`taglandin. “Pulmonary hypertension” refers to both acute
`and chronic hypertension,
`including primary pulmonary
`hypertension and secondary pulmonary hypertension, and is
`associated with an elevated pulmonary arterial pressure over
`normal levels.
`
`The efficacy of benzindene prostaglandins, such as
`UT—15, for treating pulmonary hypertension can be assessed
`by determining the hemodynamics associated with pulmo-
`nary hypertension. In particular, measurements of pulmo-
`nary arterial pressure (PPA),
`left atrial pressure (PLA),
`central venous pressure (PCV), systemic arterial pressure
`(PSYS), heart rate (HR), and cardiac output (C0) are useful
`in determining the effects of benzindene prostaglandins
`delivered by inhalation or parenterally.
`Although pulmonary arterial pressure can be directly
`measured and is often used to quantify pulmonary arterial
`hypertension, PPA can be affected by 3 other variables: CO,
`PLA and PVR, as indicated by Equation 1:
`
`8
`
`Systems T101 Ultrasonic Bloodfiow Meter (Ithaca,
`The pressure and blood flow signals may be recorded on
`ASTROMED MT—9500 Stripchart Recorder (West Warwick,
`RI.) and digitally recorded with a personal computer using
`Easy Data Acquisition Software (Nashville, Tenn.).
`It has been discovered that aerosolized UT—15 has both
`
`greater potency and efficacy relative to attenuating chemi-
`cally induced pulmonary hypertension as shown by an
`increase in pulmonary vascular resistance. Furthermore,
`aerosolized UT—15 has a greater potency as compared to
`intravascularly administered UT—15, since the actual amount
`of UT—15 delivered via aerosolization delivery is only a
`fraction (10—50%) of the dosage delivered intravascularly.
`While the mechanism(s)
`that accounts for the greater
`potency and efficacy for aerosolized UT—15 is unknown, it
`can be hypothesized that a low “first-pass” uptake via
`intravenous infusion of UT-15 could be at least partially
`responsible. A low first-pass uptake would thus allow the
`majority of the drug to be made available to the peripheral
`circulation (including the coronary circulation), which
`would increase the heart rate and cardiac output.
`Aerosolized UT—15 has no apparent peripheral effects,
`such as on the heart rate or cardiac output, as compared to
`intravascular UT—15 during pulmonary vascular hyperten-
`sion by chemical inducement. This is particularly beneficial
`for those patients that are near right heart failure and where
`peripheral vasodilation would exacerbate the challenge to
`the right heart. On the other hand,
`if cardiac output
`is
`compromised due to right heart failure, then aerosolized
`prostaglandin would decrease PVR and could allow cardiac
`output to increase while allowing lowering the load upon the
`right heart.
`The following examples are provided by way of an
`illustration of the present invention and should in no way be
`construed as constituting a limitation thereof.
`EXAMPLES
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`Example I
`
`PPA=(C0 * PVR)+PLA
`
`(1)
`
`40
`
`Animal Model
`
`As can be seen from Equation 1, PPA can be elevated by
`increases in PLA (e.g.,
`left heart failure, mitral valave
`stenosis, mitral valve regurgitation), increases in CO (e.g.,
`low hematocrit, peripheral vasodilation, left to right shunt,
`etc.), and by increases in PVR (decreased pulmonary vas-
`cular surface area, decreased pulmonary vascular radii,
`pulmonary vascular obstructions, etc.).
`On the other hand, PVR can not be directly measured and
`must be calculated by the following Equation 2:
`
`PVR=(PPA—PLA)/C0
`
`(2)
`
`PVR is a better index of pulmonary arterial hypertension
`(PAH), since interventions used to treat PAH are best if they
`only affect PVR and have no or li